Total Funding
54
30
Total FundingPost-IPO Debt raised
Growth Score
-1 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
163356
Tricida operates in the healthcare industry focusing on pharmaceutical business.
Gerrit Klaerner: Founder, Chief Executive Officer & PresidentPast Role: Relypsa, President & Founder ,Member of Board of Directors
Wilhelm Stahl: Chief Technology Officer & EVP Technical OperationsPast Role: Relypsa, SVP Pharmaceutical Operations & Chief Technology Officer
About the Company
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to
accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
